Skip to content
value.today

Genomatica Inc.

Total raised
$172 M
3 rounds on record
Latest round
$119 M
May 2021
First round on record
Jul 2012
Today
Private
No later event on record

Funding rounds

3 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Genomatica Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
May 2021$119 MNo. 3$50 to $250 million

Genomatica Inc.: Raise no. 3, May 2021

Investors in this round

11 investors had bought by the notice of Aug 10, 2021: 11 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$119 M of $119 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Carlos A. Cabrera · Executive Officer, Director
  • Christophe Schilling · Executive Officer, Director
  • David Bendsen Muldoon · Executive Officer
  • Rasmus Bendsen von Gottberg · Executive Officer
  • Thomas Bendsen McDonald · Executive Officer
  • Anders Bendsen Spohr · Director
  • Craig A. Binetti · Director
  • Eli A. Casdin · Director
  • Jason A. Kelly · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Tom McDonald, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 10, 2021. Read the notice at the SEC.

equitySEC
Feb 2014$7 MNo. 2$2 to $10 million

Genomatica Inc.: Raise no. 2, Feb 2014

Investors in this round

12 investors had bought by the notice of Mar 7, 2014: 12 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$7 M of $12 M offered; $6 M still to sell
Smallest investment taken
no minimum stated
What was sold
debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Securities offered consist of promissory notes convertible into shares of preferred stock, warrants exercisable for shares of preferred stock and the underlying preferred and common stock issuable upo
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christophe Schilling · Executive Officer, Director
  • Jeff J.G. Lievense · Executive Officer
  • Mark J.G. Burk · Executive Officer
  • Michael J.G. Keane · Executive Officer
  • William H. Baum · Executive Officer, Director
  • Geoff H. Duyk · Director
  • Josh H. Green · Director
  • Just J.G. Jansz · Director
  • Leighton J.G. Read · Director
  • Thomas J.G. Huot · Director
  • Warren H. Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts listed under Total Offering Amount & Total Remaining To Be Sold include an aggregate of $5,427,660 receivable by the Issuer upon the exercise of warrants to purchase shares of the Issuer's Preferred Stock. Such warrants have not been exercised.”

Signed by Michael Keane, Chief Financial Officer. Source: SEC Form D, newest notice filed Mar 7, 2014. Read the notice at the SEC.

debt, optionsSEC
Jul 2012$46 MNo. 1$10 to $50 million

Genomatica Inc.: Raise no. 1, Jul 2012

Investors in this round

10 investors had bought by the notice of Aug 15, 2012: 10 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$46 M of $112 M offered; $66 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Securities offered consist of convertible preferred stock, warrants exercisable for shares of convertible preferred stock and the underlying preferred and common stock issuable upon the exercise or co
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Christophe Schilling · Executive Officer, Director
  • Mark J.G. Burk · Executive Officer
  • Michael J.G. Keane · Executive Officer
  • William H. Baum · Executive Officer, Director
  • Geoff H. Duyk · Director
  • Josh H. Green · Director
  • Leighton J.G. Read · Director
  • Michael J.G. Savage · Director
  • Thomas J.G. Huot · Director
  • Warren H. Clark · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Amounts listed above include an aggregate of $11,866,442 receivable by the Issuer upon the exercise of warrants to purchase shares of the Issuer's Preferred Stock. Such warrants have not been exercised.”

Signed by Michael Keane, Chief Financial Officer. Source: SEC Form D, newest notice filed Aug 15, 2012. Read the notice at the SEC.

equity, optionsSEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Genomatica Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2021).

    SEC Form D · Aug 2021

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Aug 2021

That is all the official record says: Genomatica Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: the address on record now leads to another company's site.

Investors#

No investor of Genomatica Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 3 rounds above had up to 12 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Genomatica Inc.
NameRoleNamed in
Carlos A. CabreraExecutive officerAug 2021
Christophe SchillingExecutive officerAug 2021
David Bendsen MuldoonExecutive officerAug 2021
Rasmus Bendsen von GottbergExecutive officerAug 2021
Thomas Bendsen McDonaldExecutive officerAug 2021
Jeff J.G. LievenseExecutive officerMar 2014
Mark J.G. BurkExecutive officerMar 2014
Michael J.G. KeaneExecutive officerMar 2014
William H. BaumExecutive officerMar 2014
Anders Bendsen SpohrDirectorAug 2021
Carlos A. CabreraDirectorAug 2021
Christophe SchillingDirectorAug 2021
Craig A. BinettiDirectorAug 2021
Eli A. CasdinDirectorAug 2021
Jason A. KellyDirectorAug 2021
Geoff H. DuykDirectorMar 2014
Josh H. GreenDirectorMar 2014
Just J.G. JanszDirectorMar 2014
Leighton J.G. ReadDirectorMar 2014
Thomas J.G. HuotDirectorMar 2014
Warren H. ClarkDirectorMar 2014
William H. BaumDirectorMar 2014
Michael J.G. SavageDirectorAug 2012

About

American biotechnology company.